Trial Profile
Recombinant Anti-EGFR Monoclonal Antibody SCT200 in Patients With Advanced Solid Tumors or Lymphoma : A Phase Ⅰb, Open-label, Multicenter Study.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Jun 2020
Price :
$35
*
At a glance
- Drugs SCT 200 (Primary)
- Indications Gallbladder cancer; Gastric cancer; Liver cancer; Lymphoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Sinocelltech
- 10 Oct 2018 New trial record